112 related articles for article (PubMed ID: 35272880)
1. The Effect of Alendronate on Bone Mineral Disorder in Renal Transplant Patients.
Uçar ZA; Sinangil A; Koç Y; Barlas IS; Ecder ST; Akin EB
Transplant Proc; 2022 Apr; 54(3):658-662. PubMed ID: 35272880
[TBL] [Abstract][Full Text] [Related]
2. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
3. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
Cesareo R; Di Stasio E; Vescini F; Campagna G; Cianni R; Pasqualini V; Romitelli F; Grimaldi F; Manfrini S; Palermo A
Osteoporos Int; 2015 Apr; 26(4):1295-302. PubMed ID: 25524023
[TBL] [Abstract][Full Text] [Related]
4. Alendronate is effective to treat bone loss in renal transplantation recipients.
Lan G; Peng L; Xie X; Peng F; Wang Y; Yu S
Transplant Proc; 2008 Dec; 40(10):3496-8. PubMed ID: 19100422
[TBL] [Abstract][Full Text] [Related]
5. Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin, and calcium plus vitamin D3.
Gilfraguas L; Guadalix S; Martinez G; Jodar E; Vara J; Gomez-Sanchez MA; Delgado J; De La Cruz J; Lora D; Hawkins F
Prog Transplant; 2012 Sep; 22(3):237-43. PubMed ID: 22951500
[TBL] [Abstract][Full Text] [Related]
6. Alendronate for treatment of renal transplant patients with osteoporosis.
Torregrosa JV; Moreno A; Gutierrez A; Vidal S; Oppenheimer F
Transplant Proc; 2003 Jun; 35(4):1393-5. PubMed ID: 12826169
[TBL] [Abstract][Full Text] [Related]
7. Impact of hepatitis C virus infection on bone mineral density in renal transplant recipients.
Huang WH; Yu MC; Huang JY; Lai PC
PLoS One; 2013; 8(5):e63263. PubMed ID: 23675468
[TBL] [Abstract][Full Text] [Related]
8. The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: a prospective study.
Sahin G; Yasar NS; Sirmagul B; Bal C; Yalcin AU
Ren Fail; 2008; 30(10):992-9. PubMed ID: 19016151
[TBL] [Abstract][Full Text] [Related]
9. Alendronate prevents further bone loss in renal transplant recipients.
Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate.
Jeffery JR; Leslie WD; Karpinski ME; Nickerson PW; Rush DN
Transplantation; 2003 Nov; 76(10):1498-502. PubMed ID: 14657693
[TBL] [Abstract][Full Text] [Related]
11. Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate.
Cruz DN; Brickel HM; Wysolmerski JJ; Gundberg CG; Simpson CA; Kliger AS; Lorber MI; Basadonna GP; Friedman AL; Insogna KL; Bia MJ
Am J Transplant; 2002 Jan; 2(1):62-7. PubMed ID: 12095058
[TBL] [Abstract][Full Text] [Related]
12. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
[TBL] [Abstract][Full Text] [Related]
13. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
[TBL] [Abstract][Full Text] [Related]
15. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
[TBL] [Abstract][Full Text] [Related]
17. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
18. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
19. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Hejdova M; Palicka V; Kucera Z; Vlcek J
Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
[TBL] [Abstract][Full Text] [Related]
20. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
